• About Us
  • Science
    • Vaccines
    • Antibodies
  • Our Pipeline
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Company Profile
    • Advisors
    • Corporate Governance
    • 2024 Capital Raise
  • Resources
    • News
    • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

February 2018 Report

by admin | Feb 15, 2018 | Hardman & Co Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

September 2016 Report

by admin | Sep 26, 2016 | Hardman & Co Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Recent Posts

  • Investor Update: 24 April 2025
  • Scancell’s new partnership with the NHS Vaccine Launch Pad (CLVP) March 2025
  • Partnership with NHS Cancer Vaccine Launch Pad Enabling Fast-Tracked Access for Melanoma Patients
  • Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting
  • AACR 10 (American Association for Cancer Research), February 2025, Los Angeles, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

VACCINES

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2025 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy